BioInvent: New BI-1808 and BI-1206 data - Redeye

Redeye is bullish about the new results with BI-1808 in cutaneous T-cell lymphoma. The path towards a market approval for BI-1808 is beginning to look clearer. The BI-1206 data are also interesting but more difficult to interpret at this early stage of the trial.

Länk till analysen i sin helhet: https://www.redeye.se/research/1108668/bioinvent-new-strong-bi-1808-and-bi-1206-data?utm_source=finwire&utm_medium=RSS